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Abstract: The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: 
(1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin 
(mTOR). The latter category includes everolimus and temsirolimus, both approved for distinct indications in mRCC. Everolimus gained 
its approval on the basis of phase III data showing a benefit in progression-free survival relative to placebo in patients previously treated 
with sunitinib and/or sorafenib. In contrast, temsirolimus was approved on the basis of a phase III trial in treatment-naïve patients with 
poor-risk mRCC, demonstrating an improvement in overall survival relative to interferon-alfa. While these pivotal trials have created 
unique positions for everolimus and temsirolimus in current clinical algorithms, the role of mTOR inhibitors in mRCC is being steadily 
revised and expanded through ongoing trials testing novel sequences and combinations. The clinical development of mTOR inhibitors 
is outlined herein.
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Introduction
The management of metastatic renal cell carcinoma 
(mRCC)  has  been  revolutionized  by  the  advent  of 
  targeted therapies. A decade ago, use of immunother-
apy predominated. Agents such as interleukin-2 (IL-2) 
have demonstrated the potential to generate   durable 
complete responses (CRs), albeit in a relatively small 
proportion  of  patients  (,10%).1  Another  oft-used 
immunotherapeutic  strategy,    interferon-alfa  (IFN-α), 
led to only modest improvements in clinical outcome 
when compared in randomized trials to supportive drugs 
such as   medroxyprogesterone.2 Despite these sobering 
results, it was recommended in 2002 that IFN-α rep-
resent the comparator arm in future studies of targeted 
agents.3 Since that time, the landscape of mRCC ther-
apy has changed dramatically, with a total of six novel 
agents approved for this indication. Of these agents, 
four antagonize signalling via the vascular endothelial 
growth factor receptor (VEGFR), either by consump-
tion of ligand (i.e.   bevacizumab) or inhibition of the 
tyrosine kinase domain (i.e.   sunitinib, sorafenib and 
pazopanib).4–8  In  contrast  to  these  VEGFR-directed 
therapies, the remaining two agents, everolimus and 
temsirolimus, antagonize signalling via the mammalian 
target of rapamycin (mTOR).9,10 Outside of a distinct 
mechanism, these agents have unique considerations 
with respect to both safety and efficacy. Herein, the 
clinical  development  of  mTOR  inhibitors  and  their 
  current application in mRCC is outlined.
Mechanism of Action
mTOR  is  a  serine/threonine  kinase  measuring 
289 kDa, and is a member of the phoshatidylinositol-
3-  phosphate (PI3K) family of proteins.11 These PI3K 
family proteins play a role in cell cycle   checkpoint 
  regulation  through  a  variety  of  mechanisms.12 
  Activation of Akt, as noted in Figure 1, is initially 
  triggered first by interaction of an extracellular ligand 
with a transmembrane receptor tyrosine kinase.13,14 
Autophosphorylation of the internal domain of the 
kinase triggers activation of PI3K, subsequently acti-
vating Akt. Activation of Akt is potentially abrogated 
by the tumor suppressor phosphatase and tensin homo-
logue gene on chromosome 10 (PTEN).15 Frequently, 
loss  of  PTEN  results  in  increased  Akt-  mediated 
  signalling  and  enhanced  cell  growth  and  division. 
Downstream of Akt are the tuberous   sclerosis com-
plexes 1 and 2 (TSC1 and TSC2).16,17 These moieties 
are inhibited by Akt, releasing inhibition on the mTOR 
complex  downstream.  Two  distinct  complexes  of 
mTOR exist, mTORc1 and mTORc2—only the former 
is susceptible to inhibition by rapamycin analogues.18 
When activated, mTORc1 triggers increased transcrip-
tion  via  several  mediators,  including  p70S6K  and 
4E-BP1.19 As opposed to abrogating mTOR kinase 
activity,  the  mTOR  inhibitors  prevent  the  associa-
tion of mTOR and mLST8 in the mTORc1 complex at 
pharmacologically achievable doses, thereby inhibit-
ing   downstream signalling.20
Temsirolimus
Single agent temsirolimus: Phase I data
The  Developmental  Therapeutic  Branch  of  the 
National Cancer Institute first identified the   antitumor 
activity of temsirolimus.21 In preclinical models, it 
appeared  that  the  agent  decreased  proliferation  of 
murine  xenografts  bearing  various  solid  tumors, 
including glioma, breast and prostate cancer.22–24 In a 
phase I trial evaluating temsirolimus in patients with 
advanced cancer, 24 patients were treated at doses 
ranging from 7.5 to 220 mg/m2 intravenous weekly.25 
Doses  limiting  toxicities  (DLTs)  were  observed  at 
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Figure  1.  Signalling  via  mTOR  relevant  to  renal  cell  carcinoma 
  pathogenesis.  (Adapted  with  permission  from  Pal  SK,  Figlin  RA, 
  Reckamp KL: The role of targeting mammalian target of rapamycin in lung 
cancer. Clin Lung Cancer 9:340–5, 2008.)Treatment options in mRCC
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220 mg/m2, including acneiform rash, stomatitis and 
mucositis, all of which resolved after discontinuation 
of therapy. Pharmacokinetic data from the study indi-
cated that a flat dosing schema was appropriate for 
the agent. In this preliminary experience, confirmed 
partial responses (PRs) were observed in two patients 
with mRCC and breast cancer, respectively. Notably, 
the patient with mRCC had documented progression 
with prior IL-2 and IFN-α therapy.
Temsirolimus in combination with other 
agents approved for mRCC
Relevant to the therapy of mRCC, several phase I 
experiences have assessed the combination of tem-
sirolimus  with  other  VEGFR-targeted  therapies. 
  Fischer et al reported a trial sunitinib and temsiroli-
mus  in  patients  with  refractory  mRCC.26  Unfortu-
nately, two DLTs were noted within the first cohort 
of three patients using a starting dose of temsirolimus 
of 15 mg intravenous weekly and sunitinib 25 mg 
oral daily (on a conventional 4 week on, 2 week off 
regimen). In light of the low starting dose with these 
compounds, the study was ultimately abandoned.
The combination of temsirolimus and   bevacizumab 
appears  to  be  better  tolerated  in  the  context  of 
mRCC.27,28 In a phase I/II study, patients with clear 
cell mRCC that had progressed on up to 2 prior regi-
mens were enrolled. In the phase I component, a best 
response of PR was observed in seven patients amongst 
a total of 12 evaluable patients.27 DLTs incurred in the 
phase I component included hypertriglyceridemia and 
mucositis, and a recommended phase II dose of beva-
cizumab 10 mg/kg intravenously every 2 weeks with 
temsirolimus  25  mg    intravenously  every  week  was 
established. With data available for 35 of 40 patients in 
the phase II experience, 4 patients (16%) had PRs and 
18 patients (72%) had SD.28 Given the considerable 
clinical benefit, a phase IIIb trial has been launched to 
assess this regimen. In the INTORACT study, a total of 
800 patients will be randomized to either bevacizumab 
with everolimus or bevacizumab with temsirolimus.29
Although little data is available for the combination 
of sorafenib and temsirolimus in mRCC, a phase I/II 
trial in melanoma has assessed this regimen. In this 
trial, patients with stage IV or unresectable melanoma 
were treated with sorafenib twice daily with weekly 
intravenous temsirolimus.30 In this study, a maximally 
tolerated dose (MTD) of sorafenib 600 mg oral daily 
with  temsirolimus  25  mg  intravenous  weekly  was 
identified. With 21 evaluable patients, 9 patients had 
stable  disease  (SD)—no  responses  were  recorded. 
DLTs observed in this study were thrombocytopenia, 
hand-foot syndrome (HFS), liver function test (LFT) 
abnormalities and hypertriglyceridemia. Notably, the 
this combination have been incorporated in the ran-
domized, phase II BeST study in mRCC.31
In a phase I/II study, temsirolimus was   combined 
with  IFN-α  in  71  patients  with  mRCC.32  In  this 
study, the recommended phase II dose was ultimately 
  temsirolimus 15 mg intravenous weekly and 6 million 
units  (MU)  of  IFN-α  administered  subcutaneously 
three times per week in light of stomatitis, fatigue 
and  nausea/vomiting  observed  at  higher  doses.  In 
39 patients treated at this recommended dose, PRs 
were observed in 8% of patients and SD $ 24 weeks 
was  observed  in  36%  of  patients,  with  a  median 
  progression-free    survival  (PFS)  of  9.1  months.  A 
phase III experience with temsirolimus in mRCC is 
described subsequently.10,33
Temsirolimus with other targeted agents
A phase I/II study assessed erlotinib with temsirolimus 
in patients with recurrent malignant gliomas.34 The 
phase I component of this trial enrolled 22 patients, 
with DLTs of rash, mucositis and LFT abnormalities 
occurring beyond the MTD (determined to be erlotinib 
150 mg oral daily with temsirolimus 15 mg intrave-
nous weekly). Temsirolimus with hormonal therapy 
(i.e. letrozole) has also been assessed in the setting of 
metastatic breast cancer. In a phase II study includ-
ing 92 heavily pre-treated patients, the combination 
resulted in a clinical benefit rate (complete response, 
CR, plus PR plus SD) of 82%.35
Phase III data for temsirolimus in mRCC
The encouraging data for temsirolimus as a single 
agent  or  with  IFN-α  in  mRCC  spurned  a  pivotal 
phase III trial. In this study, a total of 626 treatment-
naive patients were identified with poor-risk features 
(defined in Table 1). Importantly, the study was open 
to all histologic subtypes, and further allowed patients 
who had treated brain metastases. Patients were ran-
domized to one of three arms: (1) temsirolimus alone, 
(2) temsirolimus with IFN-α, or (3) IFN-α. Patients 
in the IFN-α group received 3 MU subcutaneously 
three times weekly, titrated up to a dose of 18 MU. Pal and Figlin
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The group receiving temsirolimus alone received the 
agent at a dose of 25 mg intravenous weekly. Finally, 
in the combination arm, patients received temsiroli-
mus at 15 mg intravenous weekly, with a starting dose 
of 3 MU of IFN-α titrated up to 6 MU subcutaneously 
three times per week. This dose was established in an 
aforementioned phase I/II study.32
The  primary  endpoint  of  this  study  was  over-
all    survival  (OS).  When  compared  to  the  IFN-α 
alone arm, little difference in OS was observed with 
combination therapy (hazard ratio, HR, 0.96, 95% 
CI  0.76–1.20;  P  =  0.70).  In  contrast,  median  OS 
improved from 7.3 to 10.9 months in the comparison 
of IFN-α to temsirolimus alone (HR 0.73, 95% CI 
0.58–0.92; P = 0.008). Response rates (RRs) did not 
differ   significantly between treatment arms, amount-
ing to an   overall RR of ,10% in all groups. The 
reported OS data have led to a category 1 recommen-
dation from the National Comprehensive Cancer Net-
work (NCCN) for use of temsirolimus in poor-risk 
patients.36 Key elements of the study are summarized 
in Table 2.
everolimus
Single agent everolimus: Phase I data
Prior to the report of everolimus activity in caner, the 
agent had been extensively studied in the setting of 
cardiac and renal transplantation.37,38 An initial phase I 
trial in advanced solid tumors explored both weekly 
and daily dosing of oral formulations of the drug.39 In 
the first phase, patients were treated with weekly doses 
ranging from 5 to 30 mg. No DLTs were observed, and 
accompanying correlative studies assessing peripheral 
blood mononuclear cells (PBMCs) showed downregu-
lation of relevant downstream moieties (i.e. p70S6K). 
In the second part of the study, patients were treated 
with weekly doses of everolimus above 30 mg and 
daily doses of 5 or 10 mg. Although the half-life of 
everolimus  (∼30  hours)  was  thought  to  facilitate 
weekly dosing of the drug, it was observed that daily 
dosing could produce more sustained target inhibition 
in preclinical models.40 Ultimately, it was determined 
that doses of 70 mg weekly and 10 mg daily could be 
satisfactorily tolerated.
everolimus in combination with other 
agents approved for mRCC
Like temsirolimus, everolimus has been explored in 
a number of combinations with other cytotoxic and 
targeted agents. The combination of everolimus and 
sorafenib has been assessed in a disease-specific phase 
I trial in patients with mRCC.41 Patients in this study 
had predominantly clear cell histology and had pro-
gressed on prior immunotherapeutic agents, VEGFR-
directed therapies and/or everolimus. With 18 patients 
enrolled, the MTD (sorafenib at 400 mg oral twice 
daily with everolimus 10 mg daily) was identified 
Table 1. Predictors of poor survival used in the pivotal, 
phase III study of temsirolimus to define study candidates. 
For enrolment, at least three of the six predictors were 
required.10
poor-risk criteria
1. Serum LDH . 1.5 times the ULN
2. Hemoglobin level , LLN
3.   Corrected serum calcium level . 10 mg/dL (2.5 mmol/L)
4.   Time from initial diagnosis of renal-cell carcinoma  
to randomization ,1 year
5. Karnofsky performance score of 60 or 70
6. Metastases in multiple organs
Table 2. Key features of the pivotal phase III trials evaluating everolimus and temsirolimus.10,55
characteristic Temsirolimus everolimus
Study population Treatment-naive patients with poor risk disease Patients who had progressed on prior   
sunitinib and/or sorafenib
Number of patients 626 410
Randomization Temsirolimus vs. temsirolimus/IFN-α vs. IFN-α everolimus/BSC vs. Placebo/BSC
Primary endpoint OS PFS
Met primary endpoint? Yes Yes
ΔPFS (P-value)* 1.9 mos (P = NR)** 3.0 mos (P , 0.001)
ΔOS (P-value) 3.6 mos (P = 0.008) 0.39 mos (P = 0.177)
Abbreviation: *BSC, best supportive care. 
*ΔPFS and ΔOS values reported for temsirolimus pertain to the comparison of temsirolimus alone to IFN-α. **To the author’s knowledge, the P-value for 
this statistic has not been reported to date.Treatment options in mRCC
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as the recommended phase II dose. DLTs incurred 
included  pulmonary  embolism,  thrombocytopenia 
and pneumonitis. A similar trial in mRCC assessed 
the combination of sunitinib and everolimus.42 In this 
experience, both daily and weekly dosing strategies 
were examined with a consistent dose of sunitinib 
37.5 mg oral daily in all cohorts. Ultimately, a dose of 
everolimus 20 mg oral weekly with sunitinib 37.5 mg 
oral daily was recommended for phase II study. Nota-
bly,  amongst  five  patients  with  confirmed  PRs  on 
study, three had non-clear cell histology.
The combination of bevacizumab with everolimus 
has also been explored in mRCC. In a phase I study in 
advanced solid tumors, a recommended phase II dose 
of bevacizumab 10 mg/kg intravenously every 2 weeks 
and everolimus 10 mg oral daily was determined.43 Nota-
bly, amongst 14 evaluable patients, seven had SD as a 
best response. A subsequent phase II study conducted 
in patients with mRCC enrolled a total of 59 patients. 
Amongst patients who completed eight weeks of treat-
ment, 21% of patients had an objective response, and an 
additional 69% had SD. Notably, grade 3/4 proteinuria 
was seen in 19% of patients enrolled in this experience; 
most other toxicities were mild. As with temsirolimus, 
the  combination  of  everolimus  with  bevacizumab  is 
now being assessed in a randomized fashion. In the 
RECORD-2 study, 360 patients will be randomized to 
bevacizumab with either everolimus or IFN-α.44 The 
estimated primary completion date is February 2012.
everolimus with other targeted  
agents/cytotoxic therapy
A  phase  II  trial  of  everolimus  with  imatinib  was 
conducted in mRCC, with the rationale that added 
  platelet-derived  growth  factor  receptor  (PDGFR) 
blockade from imatinib could contribute to the antitu-
mor effect of everolimus.45 With nine patients evalu-
able, seven had recorded PRs and two had PD. The 
regimen was noted to have moderate toxicity, with 
grade 3 toxicities including pneumonitis, angioedema, 
fatigue and thrombocytopenia. Notably, a phase I/II 
study of everolimus and imatinib in gastrointestinal 
stromal  tumor  (GIST),  where  PDGFR  has  a  well-
documented role in pathogenesis, has demonstrated 
moderate efficacy with the regimen.46
A separate phase I effort assessed a combination of 
bevacizumab, everolimus and erlotinib.47 In a cohort 
of 34 patients, an MTD and recommended phase II 
dose of bevacizumab 10 mg/kg intravenously every 
two weeks, everolimus 10 mg daily and erlotinib 75 mg 
oral daily was determined. Notably, several severe tox-
icities were encountered with this regimen, including 
nephrotic syndrome, cardiac ischemia and ventricular 
thrombosis. Of two PRs seen with this regimen, one 
was documented in a patient with mRCC. In a similar 
effort combining VEGFR-, mTOR- and EGFR-directed 
therapy, a phase I trial has explored the combination of 
  bevacizumab, everolimus and panitumumab in advanced 
solid tumors.48 DLTs of rash and mucositis were identi-
fied using bevacizumab 10 mg/kg   intravenously every 
2 weeks, everolimus 5 mg oral every other day and 
panitumumab 4.8 mg/kg   intravenously every 2 weeks. 
Amongst nine evaluable patients, SD was recorded as 
the best response in eight.
In breast cancer, several trials are examining the 
combination of everolimus with HER2-directed ther-
apies. A phase I trial of everolimus in combination 
with paclitaxel and trastuzumab included 13 heavily 
pre-treated  patients;  all  had  clinical  benefit  (either 
PR or SD) at the time of an interim analysis.49 Fur-
thermore, DLTs had not been encountered with this 
regimen to date. In a more liberal phase Ib design, 
trastuzumab  and  everolimus  is  being  examined  in 
combination with any single chemotherapeutic agent 
specified by the clinician.50 A phase I study of the dual 
EGFR and HER2 tyrosine kinase inhibitor lapatinib 
in combination with everolimus is ongoing.51
In  estrogen  receptor-positive  breast  cancer,  the 
combination  of  letrozole  and  everolimus  has  been 
examined.52  No  pharmacokinetic  interactions  were 
observed in 30 patients, and a standard dose of letro-
zole  (2.5  mg  oral  daily)  was  deemed  appropriate 
in  combination  with  everolimus  10  mg  oral  daily. 
This phase I study was followed by a randomized 
phase II effort (comparing letrozole with or without 
everolimus)  validating  the  clinical  efficacy  of  this 
combination.53
Phase III data for everolimus in mRCC
A phase II study of everolimus in mRCC used a dose 
of 10 mg oral daily.54 Patients in this study were either 
treatment-naive or had received only one prior therapy. 
Of 41 patients enrolled in this effort, 39 were evalu-
able for safety and 37 were evaluable for response. 
Clinical outcomes were impressive; median PFS and 
OS were 11.2 months and 22.1 months, respectively. Pal and Figlin
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In total, approximately 70% of patients experienced 
PFS $ 6 months.
On the basis of this encouraging data,   everolimus 
was  examined  in  a  phase  III  trial  in  patients  who 
had  received  prior  sorafenib  and/or  sunitinib 
(RECORD-1).55 In this international study, patients 
were  randomized  to  receive  either  everolimus 
(n = 272) or placebo (n = 138) in a 2:1 fashion. Both 
treatments  were  administered  in  conjunction  with 
best  supportive  care  (BSC). The  primary  endpoint 
of the study was PFS. At the time of an initial data 
cut-off, median PFS was improved from 1.9 months 
in the placebo arm to 4.0 months in the everolimus 
arm (HR 0.30, 95% CI 0.22–0.40; P , 0.0001). At 
a six-month interval, the progression-free probabil-
ity  was  26%  with  everolimus  as  compared  to  2% 
with  placebo.  No  difference  in  OS  was  observed; 
median OS with everolimus and placebo were 14.78 
and 14.39 months, respectively (HR 0.87, 95% CI 
0.65–1.17; P = 0.177).56
safety considerations with mTOR 
Inhibitors
Toxicity data from the phase III studies of   temsirolimus 
and  everolimus  point  to  unique  class  effects.10,32 
Both agents appear to affect the metabolic profile of 
the  patient.  Hypercholesterolemia  (all  grades)  was 
observed in 24% of patients receiving temsirolimus 
and in 76% of patients receiving everolimus.   Similarly, 
hyperglycemia (all grades) was seen in 26% and 50% 
of  patients  receiving  these  therapies,  respectively. 
Although present in a relatively large proportion of 
patients, the severity of these toxicities was gener-
ally  mild—few  grade  3/4  toxicities  were  recorded. 
The mechanism by which this occurs appears to be 
complex.  In  rodent  models,  while  it  appears  that 
rapamycin  reduces  de  novo  lipid    synthesis,  there 
was a parallel increase in oxygenation of exogenous 
  lipids.57 In the same models, decreased glycogen syn-
thesis  and  non-insulin-dependent  glucose  transport 
was observed, potentially explaining the hyperglyce-
mia observed with mTOR inhibitors. An intricate axis 
linking  hyperglycemia,  hyperlipidemia  and  mTOR-
related signalling has also been posited. In preclini-
cal experiments, it has been shown that rapamycin 
can block insulin-mediated phosphorylation of lipin.58 
Lipin (present in the setting of fatty liver dystrophy) 
produces    hyperlipidemia  and  defects  in  adipocyte 
  differentiation in an insulin-dependent fashion.
The occurrence of non-infectious pneumonitis is 
increasingly recognized with mTOR inhibitors. The 
most recent presentation of data from the RECORD-1 
trial  suggested  that  14%  of  patients  treated  with 
everolimus  developed  non-infectious  pneumoni-
tis; notably, these cases were reviewed by a team of 
pulmonary  specialists.56 Amongst  ten  patients  who 
developed grade 3 non-infectious pneumonitis, eight 
patients  had  complete  clinical  resolution  with  ste-
roid therapy. These data underscore the importance 
of early recognition of this potentially lethal toxicity. 
Use of imaging alone can be challenging—with serial 
review of radiographic imaging of 245 patients receiv-
ing everolimus and 132 patients receiving placebo, 
new findings were seen in a far higher percentage of 
patients receiving everolimus as compared to placebo 
(38.9% vs. 15.2%), even in the absence of a clinical 
diagnosis of pneumonitis.59 Bronchoscopic evaluation 
should be pursued, and treatment with steroid therapy 
should be instituted if infectious causes are ruled out. 
This algorithm can also be used for temsirolimus ther-
apy. A follow-up study of patients treated with tem-
sirolimus in the original pivotal trial identified only 
four cases of pneumonitis.60 However, in one of these 
cases, a patient progressed from grade 3 to 5 toxicity, 
with this death “possibly” attributed to therapy.
Other  prominent  side  effects  associated  with 
mTOR  inhibitors  include  stomatitis  and  rash.  In 
trial experiences to date, these toxicities appear to 
be manageable with standard supportive measures.60 
Hematologic  side  effects  have  also  been  observed 
with these therapies. Published recommendations for 
temsirolimus suggest holding doses for absolute neu-
trophil counts (ANCs) of less than 1000/µL, plate-
let counts of less than 75,000/µL or any other grade 
3/4  hematologic  event.60  These  recommendations 
further  suggest  that  re-initiation  of  therapy  should 
occur only when the toxicity resolves to grade 2 or 
lower. Similar strategies can be employed for therapy 
with everolimus. The clinician should also be mind-
ful of potential drug interactions in using everolimus 
and temsirolimus; strong inducers and inhibitors of 
CYP3A4 should be avoided.61 The patient should also 
be counselled against taking grapefruit juice, which 
can affect metabolism of these agents.Treatment options in mRCC
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Optimal sequence and synergy
With  a  diverse  array  of  treatment  options,  it  is 
  challenging  to  ascertain  how  the  mTOR  inhibitors 
are  most  placed  in  existing  algorithms  (Table  3). 
At the present time, use of everolimus and temsi-
rolimus in clinical practice should parallel their use 
in  the  phase  III  studies  leading  to  their  approval. 
For instance, use everolimus should be confined to 
patients who are refractory to prior VEGF-directed 
therapy.55    Furthermore,  temsirolimus  should  be 
offered  to  those  treatment-naive  patients  that  have 
poor-risk disease.10
Several  studies  may  change  these  paradigms. 
For instance, the RECORD-3 trial utilizes a unique 
design,  randomizing  patients  with  treatment-naive 
mRCC to receive either sunitinib or everolimus as 
initial therapy, followed by crossover to the oppo-
site  regimen  (Fig.  2).62  The  primary  endpoint  is 
PFS, and the study is powered to determine non-
inferiority of either regimen. If positive, the results 
of this study could suggest interchangeable use of 
sunitinib and everolimus as first-line therapy. mTOR 
inhibitors may also become incorporated in first-line 
algorithms  when  used  in  combination  with  VEG-
FR-directed  therapy  (Fig.  3).  The  aforementioned 
INTORACT  and  RECORD-2  studies,  evaluating 
bevacizumab in   combination with temsirolimus and 
everolimus, respectively, may alter the current rec-
ommendation of using bevacizumab in combination 
with IFN-α.29,44 Notably, INTORACT is structured as 
a phase IIIb study and is expected to enroll a total 
of 800 patients. In contrast, RECORD-2 (a random-
ized  phase  II  effort)  will  include  approximately 
360 patients. The primary completion date of both 
studies  is    February  2012.  Given  the  larger  scope, 
INTORACT may have a more tangible impact on 
therapeutic  decision-  making. As  previously  noted, 
the  BeST  study  will  also  include  arms  evaluating 
mTOR inhibitors in combination with VEGFR-di-
rected therapy.31 Two of the four arms in this study 
include  such  a  combination  (sorafenib  with  tem-
sirolimus,  and  bevacizumab  with    temsirolimus). 
However, in this randomized phase II effort, only 90 
patients will be accrued to each arm.
Several  questions  also  surround  the  optimal 
  second-line therapy for mRCC. Available data sug-
gests that actual practice patterns do not include sub-
stantial use of mTOR inhibitors as second-line therapy. 
In a retrospective analysis of 645 patients treated with 
sunitinib, sorafenib or bevacizumab up-front, a total 
of  218  patients  received  second-line  therapy.63  Of 
these, only 24 patients (11%) received either everoli-
mus or temsirolimus; the majority received second-
ary VEGFR-directed treatments. The data to support 
re-challenge with VEGFR-directed therapy is derived 
largely from retrospective series, though phase II data 
and an ongoing phase III trial may support the use 
of  axitinib  in  this  setting.64,65 A  lingering  question 
remains in the face of this trial—does second-line 
therapy with an mTOR inhibitor or VEGFR-directed 
agent represent the superior approach? An ongoing 
randomized trial is comparing sorafenib to temsiroli-
mus in patients who have failed prior therapy with 
sunitinib.66 The study is expected to accrue a total 
of 480 patients by May of 2011. At this time, only 
retrospective data is available to document the activ-
ity of temsirolimus in patients who are refractory to 
VEGFR-directed therapy.67
Table 3. A current, evidence-based algorithm for the management of mRCC. (Adapted from the National Comprehensive 
Cancer Network (NCCN) Clinical Practice Guidelines for Renal Cell Carcinoma, v.1.2010.)
Disease and line of therapy setting Therapy
phase III data phase II data
Clear cell RCC, first line Good/intermediate risk Sunitinib, Bevacizumab +  
IFN, Pazopanib
HD IL-2
Poor risk Temsirolimus*
Clear cell RCC, second line Prior cytokines Sorafenib  Sunitinib, bevacizumab
Prior veGFR TKI everolimus  
Prior bevacizumab Sunitinib
*Note that in the pivotal trial of temsirolimus, all histologic subtypes of mRCC were included.Pal and Figlin
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Mechanisms of Resistance  
to mTOR Inhibition
While  mTOR  inhibitors  show  substantial  clinical 
  benefit  in  general,  the  agents  appear  to  be  primar-
ily cytostatic. In most cases, disease progression will 
inevitably occur. As such, it will be critical for the 
scientific community to focus efforts on determining 
mechanisms of resistance to mTOR inhibition such that 
successful secondary strategies can be   implemented. 
Mutations in the genes encoding mTOR itself have been 
shown to induce a relative resistance to rapamycin.68,69 
  Furthermore, mutation of   downstream targets of the 
mTOR complex (i.e. S6K1) can have a similar effect.70 
Somewhat paradoxically, activation of upstream moi-
eties such as Akt may induce a relative sensitivity to 
mTOR inhibitors—this has been observed in panels 
of brain, prostate and breast cancer cells exposed to 
temsirolimus.71,72 Moving forward, it will be interesting 
to observe the clinical effect of a combined approach 
with Akt and mTOR inhibition. Akt inhibitors appear to 
RECORD-3 A
B NCT00474786
Treatment-
naÏve mRCC
Start date:
   Oct 2009
Est. completion:
   Apr 2013
No. of pts. = 390
Start date:
   July 2007
Est. completion:
   May 2011
No. of pts. = 480
Everolimus
Everolimus Sunitinib
Sunitinib
Temsirolimus
Sorafenib
mRCC
refractory to
sunitinib
Figure 2. Ongoing clinical trials evaluating the optimal sequence of mTOR inhibitors.
A
B
C
Start date:
  Nov 2008
Est. completion:
   Feb 2012
No. of pts. = 360
Start date:
   Mar 2008
Est. completion:
   Feb 2012
No. of pts. = 800
Start date:
   Sept 2007
Est. completion:
   May 2012
No. of pts. = 360
Bevacizumab
Bevacizumab
Bevacizumab
Bevacizumab
Bevacizumab
Bevacizumab
Bevacizumab
Everolimus
IFN
IFN
Temsirolimus
Temsirolimus
Temsirolimus
Sorafenib
Sorafenib
RECORD-2
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BEST
Treatment-
naÏve mRCC
Treatment-
naÏve mRCC
Treatment-
naÏve mRCC
Figure 3. Ongoing clinical trials evaluating optimal combinations of mTOR inhibitors with veGFR-directed therapy.Treatment options in mRCC
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show   moderate efficacy in the setting of mRCC; most 
notably,   substantial phase II data has accumulated for 
the agent perifosine.73,74 A phase I study of perifosine in 
combination with   temsirolimus is currently ongoing.75
conclusions
A multitude of clinical studies preceded the phase III 
trials leading to the approvals of temsirolimus and 
everolimus for mRCC. Each agent has ultimately found 
a unique application—temsirolimus in the treatment-
naive patient with poor-risk disease, and everolimus in 
the patient refractory to sunitinib and/or sorafenib. This 
is an important distinction from the VEGFR-directed 
therapies. In current algorithms, considerable overlap 
exists in the suggested use of sunitinib, bevacizumab 
and pazopanib, leaving the clinician in a state of clini-
cal equipoise. The ongoing studies of mTOR inhibitors 
(including INTORACT, RECORD-2 and RECORD-3) 
may aid in further defining the optimal sequence and 
synergy with other targeted agents. While these com-
parative  designs  may  refine  existing  algorithms,  a 
fundamental goal that remains is personalization of 
cancer treatment. The identification of biomarkers to 
predict response to therapy is critical in this process. 
As a preeminent example of this work,   Gordan et al 
have reported a unique classification of clear cell RCC 
tumors based on VHL gene status and consequent pro-
duction  of  hypoxia-inducible  factor  (HIF).76  Three 
distinct subtypes exist in this schema: (1) wild type 
(WT; VHL wild type), (2) H1H2 (VHL mutant with 
overexpression of HIF-1α and HIF-2α), and (3) H2 
(VHL mutant with overexpression of HIF-2α only). 
In gene expression studies, tumors characterized as 
either WT or H1H2 (representing ∼70% of the speci-
mens assessed) had enhanced Akt/mTOR signalling; 
in contrast, those characterized as H2 (the remainder) 
had increased c-myc signalling. Further prospective 
efforts may therefore be aimed at determining if WT 
and H1H2 tumors are particularly sensitive to mTOR 
inhibitors. Use of biomarker-based strategies to per-
sonalize care may ultimately yield the most effective 
clinical application of mTOR inhibitors.
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